Beruflich Dokumente
Kultur Dokumente
Summary
Background Individuals with a history of recurrent depression have a high risk of repeated depressive relapse or Lancet 2015; 386: 63–73
recurrence. Maintenance antidepressants for at least 2 years is the current recommended treatment, but many Published Online
individuals are interested in alternatives to medication. Mindfulness-based cognitive therapy (MBCT) has been shown April 21, 2015
http://dx.doi.org/10.1016/
to reduce risk of relapse or recurrence compared with usual care, but has not yet been compared with maintenance
S0140-6736(14)62222-4
antidepressant treatment in a definitive trial. We aimed to see whether MBCT with support to taper or discontinue
See Comment page 10
antidepressant treatment (MBCT-TS) was superior to maintenance antidepressants for prevention of depressive
Department of Psychiatry,
relapse or recurrence over 24 months. University of Oxford, Oxford, UK
(W Kuyken PhD); Mood Disorders
Methods In this single-blind, parallel, group randomised controlled trial (PREVENT), we recruited adult patients with Centre, Psychology, University
of Exeter, Exeter, UK (W Kuyken,
three or more previous major depressive episodes and on a therapeutic dose of maintenance antidepressants, from
R Hayes PhD, E Watkins PhD,
primary care general practices in urban and rural settings in the UK. Participants were randomly assigned to either C Brejcha BSc, J Cardy BSc,
MBCT-TS or maintenance antidepressants (in a 1:1 ratio) with a computer-generated random number sequence with A Causley BSc, S Cowderoy MSc,
stratification by centre and symptomatic status. Participants were aware of treatment allocation and research assessors A Evans MSc, F Gradinger PhD,
J Richards BSc, P Shah, H Sutton,
were masked to treatment allocation. The primary outcome was time to relapse or recurrence of depression, with
R Vicary PhD, A Weaver BSc,
patients followed up at five separate intervals during the 24-month study period. The primary analysis was based on J Wilks MSc, M Williams MSc);
the principle of intention to treat. The trial is registered with Current Controlled Trials, ISRCTN26666654. Centre for the Economics of
Mental and Physical Health,
King’s College London, London,
Findings Between March 23, 2010, and Oct 21, 2011, we assessed 2188 participants for eligibility and recruited
UK (B Barrett PhD, S Byford PhD);
424 patients from 95 general practices. 212 patients were randomly assigned to MBCT-TS and 212 to maintenance Primary Care Group, Plymouth
antidepressants. The time to relapse or recurrence of depression did not differ between MBCT-TS and maintenance University Peninsula Schools of
antidepressants over 24 months (hazard ratio 0·89, 95% CI 0·67–1·18; p=0·43), nor did the number of serious Medicine and Dentistry,
Plymouth, UK (R Byng PhD);
adverse events. Five adverse events were reported, including two deaths, in each of the MBCT-TS and maintenance
Medical Research Council
antidepressants groups. No adverse events were attributable to the interventions or the trial. Cognition and Brain Sciences
Unit, Cambridge, UK
Interpretation We found no evidence that MBCT-TS is superior to maintenance antidepressant treatment for the (T Dalgleish PhD); School of
Social and Community
prevention of depressive relapse in individuals at risk for depressive relapse or recurrence. Both treatments were Medicine, University of Bristol,
associated with enduring positive outcomes in terms of relapse or recurrence, residual depressive symptoms, and Bristol, UK (D Kessler PhD,
quality of life. S Kaur BSc); Division of
Psychiatry, University College
London, London, UK
Funding National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, and (G Lewis PhD); Clifton,
NIHR Collaboration for Leadership in Applied Health Research and Care South West Peninsula. Bedfordshire, UK (P Lanham);
Department of Psychology,
Copyright © Kuyken et al. Open Access article distributed under the terms of CC BY. University of Cambridge,
Cambridge, UK (N Morant PhD);
and Exeter Medical School,
Introduction depressive relapse or recurrence can be attenuated, the University of Exeter, Exeter, UK
Depression typically has a relapsing and recurrent course.1 recurrent course of depression could potentially be broken. (R S Taylor PhD)
Without ongoing treatment, individuals with recurrent Currently, most depression is treated in primary care, Correspondence to:
depression have a high risk of repeated depressive relapses and maintenance antidepressants are the mainstay Dr Willem Kuyken, Department
of Psychiatry, Warneford
or recurrences throughout their life with rates of relapse or approach for the prevention of relapse or recurrence. The Hospital, University of Oxford,
recurrence typically in the range 50–80%.2 Major inroads UK’s National Institute for Health and Care Excellence Oxford OX3 7JX, UK
into the substantial health burden attributable to (NICE) recommends that, to stay well, people with willem.kuyken@psych.ox.ac.uk
depression could be offset through interventions that a history of recurrent depression should continue
prevent depressive relapse or recurrence in people at maintenance antidepressants for at least 2 years.3
highest risk. If the factors that make people susceptible to However, adherence rates tend to be poor, maintenance
antidepressant treatment is only protective for as long as Most participants were identified through searches of
it is taken4 and is contraindicated for some groups, and computerised general practitioner (GP) practice databases
many patients express a preference for psychosocial to identify patients who were currently being prescribed a
interventions that provide long-term protection against therapeutic dose of antidepressants. PREVENT was also
relapse or recurrence. Patients at increased risk of relapse advertised locally and interested patients could self-refer.
show less protection from maintenance antidepressants GPs had the opportunity to exclude patients they felt
than do patients at low risk and many patients express a would be unsuitable and a letter of invitation was sent to
preference for psychosocial interventions that provide the remaining identified patients. Patients who expressed
long-term protection against relapse or recurrence. an interest in the trial were screened over the telephone to
Mindfulness-based cognitive therapy (MBCT) was establish potential eligibility and if suitable were invited
developed as a psychosocial intervention for teaching to attend a baseline interview.
people with recurrent depression the skills to stay well in The study was approved by the UK National Health
the long term.5 A systematic review and meta-analysis6 of Service South West Research Ethics Committee
six randomised controlled trials (n=593) suggests that (09/H0206/43) and we obtained research governance
MBCT significantly reduces the rates of depressive approval from the local primary care trusts or health
relapse or recurrence compared with usual care or boards. The trial was conducted and reported in
placebo, corresponding to a relative risk reduction of accordance with CONSORT guidelines.14,15
34% (risk ratio 0·66, 95% CI 0·53–0·82). Evidence is
accumulating that MBCT might confer most benefit to Randomisation and masking
patients at greatest risk, for example those reporting Participants were randomly allocated (in a 1:1 ratio) to
childhood adversity.7,8 A key remaining uncertainty is receive either maintenance antidepressant treatment or
whether MBCT provides an alternative for people an 8-week MBCT class that included support to taper or
wishing to discontinue antidepressants.9 On the basis of discontinue their maintenance antidepressant medication
our pilot trial,10 we tested whether MBCT with support to (MBCT-TS).
taper or discontinue antidepressant treatment Patients were randomly assigned to the two groups with
(MBCT-TS) was better than maintenance antidepressants a computer-generated random number sequence stratified
in terms of: a primary outcome of prevention of according to recruitment centre and participants’ symp-
depressive relapse or recurrence over 24 months; and tomatic status at randomisation using the GRID-Hamilton
secondary outcomes of depression-free days, residual Rating Scale for Depression (GRID-HAMD)16 cutoff of less
depressive symptoms, psychiatric and medical than 8 being asymptomatic and greater than or equal to 8
comorbidity, quality of life, and cost-effectiveness over being partially symptomatic.17 Allocation was undertaken
24 months. using a password-protected website maintained by the
Peninsula Clinical Trials Unit, independent of the trial.
Method The trial administrator informed participants of the
Study design and participants outcome of randomisation via a letter; research assessors
PREVENT was a multicentre, pragmatic, single-blind, remained masked to treatment allocation for the duration
parallel randomised controlled trial examining MBCT-TS of the follow-up period. The fidelity of this masking was
versus maintenance antidepressants. The study design moderate with assessors correctly guessing allocation for
and procedures are presented in full in in the published 56% of assessments. In view of the nature of the
trial protocol.11,12 interventions, patients and clinicians were aware of
Participants were recruited from general practices in treatment allocation.
urban and rural settings in four UK centres: Bristol,
Exeter and east Devon, north and mid Devon, and south Procedures
Devon. Inclusion criteria were a diagnosis of recurrent MBCT is a manualised, group-based skills training
major depressive disorder in full or partial remission programme designed to enable patients to learn skills that
according to the Diagnostic and Statistical Manual of prevent the recurrence of depression.18 It is derived from
Mental Disorders-IV (DSM-IV); three or more previous mindfulness-based stress reduction, a programme with
major depressive episodes; age 18 years or older; and on a proven efficacy in ameliorating distress in people with
therapeutic dose of maintenance antidepressant drugs in chronic disease, and cognitive-behavioural therapy for
line with the British National Formulary (BNF)13 and acute depression, which has shown efficacy in prevention
NICE guidance. Exclusion criteria were a current major of depressive relapse or recurrence. MBCT is intended to
depressive episode, comorbid diagnoses of current enable people to learn to become more aware of their
substance misuse; organic brain damage; current or past bodily sensations, thoughts, and feelings associated
psychosis, including bipolar disorder; persistent antisocial with depressive relapse or recurrence and to relate
behaviour; persistent self-injury needing clinical manage- constructively to these experiences. Participants learn
ment or therapy; and formal concurrent psychotherapy. mindfulness practices and cognitive-behavioural skills
All participants gave written informed consent. both in session and through homework assignments.
Therapists provide support to patients in learning to Participants were assessed at six timepoints: baseline
respond adaptively to thoughts, feelings, and experiences (before randomisation), 1 month after the end of the
that might otherwise have triggered depressive relapse. 8-week MBCT-TS programme (or the equivalent time in
The programme consists of eight 2·25 h group sessions, the maintenance antidepressant group), which varied
normally over consecutive weeks, with four refresher between 12 and 24 weeks post-randomisation, and at
sessions offered roughly every 3 months for the following 9, 12, 18, and 24 months post-randomisation.
year. Four therapists delivered 21 MBCT-TS groups in
various settings including research clinical facilities, Outcomes
hospital sites, and the community. The primary outcome measure was time to relapse or
Before therapists progressed to running trial groups, an recurrence of depression, with patients followed up at
independent check on their competency was established. five separate intervals during the 24-month period of
An experienced MBCT therapist independent of the trial study. We assessed the time between assessments
rated at least two videotapes for every potential therapist retrospectively according to the depression module of
using the Mindfulness-Based Interventions Teacher the Structured Clinical Interview for DSM–IV (SCID).21
Assessment Criteria19 and MBCT Adherence Scale We defined relapse or recurrence as an episode meeting
(MBCT-AS).20 She made an overall judgment as to whether DSM-IV criteria for a major depressive episode.11,21
the therapists were competent and adhered to the MBCT The secondary outcomes were number of depression-
manual, and therapists only progressed once competency free days, residual depressive symptoms, psychiatric
in all domains was clearly established. During the trial, the and medical comorbidity, quality of life, and
same rater assessed two sessions from each of the cost-effectiveness. At each follow-up we recorded the
21 MBCT-TS courses using the MBCT-AS, which indicated number of depression-free days based on episode
that the MBCT teaching was at required competency or duration as assessed by the SCID, residual depressive
adherence levels and above. The sessions second rated symptoms as assessed by the GRID-HAMD22 and the
were randomly selected by the trial team before the start of 21-item self-report Beck Depression Inventory (BDI),23
the intervention, and therapists were unaware which of psychiatric comorbidity using the relevant SCID
their sessions would be assessed. During the trial, modules and medical comorbidities using the Medical
therapists received group supervision every 2 weeks for 3 h. Symptom Checklist (MSCL), quality of life using the
Patients in the MBCT-TS group received support to WHO Quality of Life instrument (WHOQOL-BREF),24
taper or discontinue their maintenance antidepressants and health-related quality of life using the EQ-5D-3L
both from the MBCT-TS therapist and their GPs. The (three level version).25,26
study team provided guideline information to GPs and The economic perspective included all hospital and
patients about typical tapering or discontinuation community health and social services, plus productivity
regimens and possible withdrawal effects. The guidelines losses, known to be a substantial cost in depression.27
recommended that patients began a tapering regimen We obtained MBCT group data from therapist records.
after 6 weeks of treatment; however, GPs and patients We obtained data on indirect time related to MBCT
determined the tapering or discontinuation regimen. delivery, including preparation and supervision, from
Letters signed by the chief investigator and trial GP (RB) trial therapists. We obtained data on drugs and use of
were sent to patients’ GPs and copied to the patient, all other services using the Adult Service Use Schedule
prompting the GP to have a discussion with the patient (AD-SUS) at each follow-up, modified and successfully
about a suitable tapering or discontinuation regimen used in our previous MBCT trial.10 We confirmed ADM
after 4–5 weeks of the MBCT-TS group sessions. At the prescriptions and GP contacts via GP records. We
end of the eight MBCT-TS sessions, another letter measured productivity losses as a result of time off
was sent reminding the GP to ensure a tapering or work or reduced productivity at work due to illness
discontinuation regimen was in place. using the absenteeism and presenteeism questions
Patients in the maintenance antidepressant group of the WHO’s Health and Work Performance
received support from their GPs to maintain a therapeutic Questionnaire (HPQ).28
level of antidepressant medication in line with BNF13 and All unit costs were for the financial year 2011–12, and
NICE guidelines for the 2-year follow-up period. costs and quality-adjusted life-years (QALYs) incurred in
As described fully in the trial protocol,11,12 we encouraged the second year were discounted by 3·5% as recommended
all participants to adhere to medication for the full length by NICE.29 We calculated the cost of MBCT-TS directly
of the trial by writing to all trial participants and their from salaries using a micro-costing approach used in our
GPs after every follow-up reminding them that the trial previous trial.10 We applied national UK unit costs to
was seeking to compare staying on antidepressants for medication and all other health and social services. We
2 years with taking part in mindfulness classes and calculated productivity losses using the friction cost
tapering or discontinuation of antidepressant treatment. approach for absenteeism30 and using the method set out
However, patients remained in the trial whatever by Kessler and colleagues28 for presenteeism. The
treatment choices they made. appendix shows full details of all unit costs. See Online for appendix
8989 GP excluded
1764 excluded
1120 not eligible
644 declined
424 randomised
Statistical analysis
MBCT-TS (n=212) m-ADM (n=212)
The study was powered to detect a hazard ratio of 0·6310
between the two treatments at 24 months for the primary Demographic characteristics
outcome, with 90% power, two-sided 5% α level, assuming Women 151 (71%) 174 (82%)
a small clustering effect (intraclass correlation=0·01) and White ethnic origin 210 (99%) 210 (99%)
allowing for 20% loss to follow-up, producing a target Age, years
sample size of 420 (210 per group). All analyses were Mean (SD) 50 (12) 49 (13)
prespecified in a detailed statistical analysis plan that was Range 22–78 20–79
reviewed by the independent Trial Data Monitoring and Marital status
Steering Committees. Analyses were undertaken Single 42 (20%) 38 (18%)
according to the intention-to-treat principle except where Married, cohabiting, or civil partnership 125 (59%) 140 (66%)
stated. Separated, divorced, or widowed 44 (21%) 33 (16%)
The primary analysis was a between group comparison Missing 1 (<1%) 1 (<1%)
of time to relapse or recurrence at 24 months using a Education
Cox regression proportional hazards model adjusted for No educational qualification 10 (5%) 10 (5%)
stratification variables. We did two predefined secondary O levels or GCSEs 36 (17%) 45 (21%)
analyses of the primary outcome comparing groups AS and A levels or vocational qualification 84 (40%) 92 (43%)
according to whether participants had received an adequate University training 77 (36%) 61 (29%)
dose of treatment and adhered to treatment as invited. We Missing 5 (2%) 4 (2%)
defined an adequate dose of treatment for MBCT-TS as Religion
attending four or more group sessions and for maintenance Christian 133 (63%) 139 (66%)
antidepressants as a BNF therapeutic dose of Other 10 (5%) 4 (2%)
antidepressants during the 24-month follow-up period. We None 68 (32%) 68 (32%)
defined adherence to treatment as invited for MBCT-TS as Missing 1 (<1%) 1 (<1%)
attending four or more classes and at some point Salary (£)
discontinuing or reducing antidepressants; for Mean (SD) £19 930 (13 387) £18 024 (13 582)
maintenance antidepressants, we defined adherence as a Range £1200–£72 000 £792–£80 000
BNF therapeutic dose throughout the 24-month follow-up. Social class
We compared secondary outcomes across all timepoints Class 0 96 (45%) 76 (36%)
using repeated measures mixed regression models.
Class 1 53 (25%) 52 (25%)
Missing data were assumed missing at random and
Class 2 22 (10%) 38 (18%)
sensitivity analysis examined the effect of missing data
Class 3 5 (2%) 6 (3%)
using multiple imputations.31 We report between group
Class 4 0 2 (1%)
inference for secondary outcome analyses based on
Class 5 35 (17%) 37 (17%)
complete case and imputed datasets.
Not classified 1 (<1%) 1 (<1%)
We used interaction terms to undertake predefined
Stratification variables
exploratory subgroup analyses on the primary outcome,
Depressive symptomology at randomisation
across the stratification variables (recruitment centre and
Asymptomatic 163 (77%) 162 (76%)
baseline depression severity) and reported childhood
Symptomatic 49 (23%) 50 (24%)
abuse.12,32 Participants in the high abuse group reported
Recruitment site
experiencing childhood physical or sexual abuse or scored
above the median score for the Measure of Parenting Scale Bristol 33 (16%) 31 (15%)
(MOPS)33 abuse subscale. Participants completed the Exeter and east Devon 72 (34%) 76 (36%)
MOPS at baseline as part of an embedded process-outcome North and mid-Devon 55 (26%) 54 (25%)
study.11 The abuse subscale asks participants to indicate South Devon 52 (25%) 51 (24%)
how true they felt certain statements about their parents’ Psychiatric characteristics
behaviour were: for example, “parent was physically violent Current depressive symptomology GRID-HAMD 4·8 (4·3) 4·6 (4·3)
or abusive of me; parent made me feel unsafe”. Participants Current depressive symptomology BDI-II score 13·8 (10·2) 14·5 (10·1)
in the low reported childhood abuse group scored below Previous major depressive episodes
the median score for the MOPS abuse subscale and did <6 episodes 120 (57%) 106 (50%)
not report childhood physical or sexual abuse. ≥6 episodes 92 (43%) 106 (50%)
We analysed differences in mean costs using standard Age (years) at first depression onset 24·4 (11·5) 25·4 (13·3)
parametric t tests with the validity of results confirmed Time (months) since last depressive episode 21·2 (27·0) 17·1 (23·0)
using bias-corrected, non-parametric bootstrapping Number of comorbid DSM-IV axis I psychiatric 0·5 (0·9) 0·7 (0·9)
(repeat re-sampling).34,35 The primary economic analysis diagnoses
compared MBCT-TS and maintenance antidepressant (Table 1 continues on next page)
treatment from the health and social care perspective
m-ADM=maintenance antidepressant medication. MBCT-TS=mindfulness-based cognitive therapy with support to taper or discontinue antidepressant medication. BDI=Beck Depression Inventory.
GRID-HAMD=GRID Hamilton Rating Scale for Depression. MSCL=medical symptom checklist. WHO-QoL=WHO Quality of Life. *p values reported are the treatment group-time interaction contrasts of marginal
linear predictions for observed data. †p values reported are the treatment group-time interaction contrasts of marginal linear predictions for including imputed data. All models adjusted for baseline depression
severity category on Hamilton scale and centre.
Table 4: Intention-to-treat repeated measures amalyses at 1 month after treatment, and follow-up at 9, 12, 18, and 24 months for secondary outcomes
Data are mean (SD) unless otherwise stated. MBCT-TS=mindfulness-based cognitive therapy with support to taper or discontinue antidepressant medication.
MBCT=mindfulness-based cognitive therapy. PSS=personal social services. *Adjusted for stratification variables.
Table 5: Mean cost per participant over the 24-month follow-up period (£)
Serious adverse events were monitored and a total of ten Across both treatment groups, outcomes were
serious adverse events were reported, four of which comparatively good over the 2 years of follow-up in terms
resulted in the death of the participant. These adverse of relapse or recurrence, residual symptoms, and quality
events were evenly split between the two trial groups of life (table 4).
(three non-fatal and two fatal serious adverse events in Consistent with an emergent pattern of findings,7
each group) and reported to the Trial Steering and Data MBCT might confer most benefit to patients at greatest
Monitoring Committees who concluded that there was no risk of relapse. A randomised trial7 of patients with a
reason to believe that any of the serious adverse events history of three or more episodes of depression (n=274)
were related to either the intervention or the trial. compared MBCT, psycho-education, and usual care
over a 12-month follow-up. MBCT provided significant
Discussion protection against relapse or recurrence for participants
We noted no evidence for the superiority of MBCT-TS with increased risk due to history of childhood abuse,
compared with maintenance antidepressants for patients but showed no significant advantage over the whole
with recurrent depression in terms of the primary outcome group.7 Findings from trials of psychosocial approaches
of time to depressive relapse or recurrence over 24 months have shown that more intensive psychosocial
or any of the secondary outcomes. Cost-effectiveness treatments confer protection for those most at risk. For
analysis does not support the hypothesis that MBCT-TS is example, in a two-arm randomised trial over a 21-month
more cost effective than maintenance antidepressants, in follow-up, relapse or recurrence rates were 51% for
terms of either relapse or recurrence or QALYs. maintenance cognitive behavioural therapy (CBT) and
Before this study, only two small studies10,39 had 60% for psycho-education, but in those at greatest risk,
compared MBCT-TS with maintenance antidepressants CBT conferred greater protection than did
(panel). In our pilot trial,10 MBCT-TS (n=62) was psycho-education.40 A reported history of abuse and
compared with maintenance antidepressant treatment adversity is associated with worse outcomes in people
(n=61) over a 15-month follow-up, and relapse or who have depression.41 Perhaps MBCT confers
recurrence rates were 47% for MBCT-TS, compared with resilience in this group at highest risk because patients
60% for maintenance antidepressants.10 In the second learn skills that address some of the underlying
study,39 84 patients with recurrent depression who had mechanisms of relapse or recurrence, a question we
remitted on antidepressants were randomly assigned to will explore in a subsequent publication from this trial.
MBCT-TS, maintenance antidepressants, or pill placebo. Studies are needed that have the primary aim of
Relapse or recurrence rates noted over 18 months of establishing the effectiveness and mechanism of MBCT
follow-up did not differ for MBCT-TS (28%, n=5/18) and for those at differing levels of risk of relapse, with
maintenance antidepressants (27%, n=3/11), but both robust measures of risk.
were lower than with placebo (71%, n=10/14).39 This largest trial of any mindfulness-based approach to
Relapse or recurrence rates in people with three or date answered an important clinical question of high
more previous episodes are as high as 80% over 2 years.2 relevance to GPs and patients at risk for depressive
Moreover, results from meta-analyses consistently relapse or recurrence. The internal validity of the trial
suggest that maintenance antidepressant treatment was established through the fidelity of MBCT-TS delivery,
reduces the odds of relapse by two-thirds or a halving of high rates of treatment adherence, excellent retention,
absolute risk compared with usual care or placebo.4 and through masked outcome assessment. The external
Future research should therefore examine the hypothesis validity was maximised by the relatively long follow-up
that MBCT-TS would provide benefits over and above (24 months), and good adherence rates in both treatment
either usual care, no treatment, or pill placebo. groups.
Beverley Herring and other service users who brought their personal lived 18 Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based
experience of depressive illness to advise on the direction of the trial and cognitive therapy for depression, 2nd edn. New York: Guilford
provide training for the research assessors. We acknowledge the SCID and Press, 2013.
GRID-HAMD training that Sandra Kennell-Webb provided to our research 19 Crane RS, Eames C, Kuyken W, et al. Development and validation
staff. We thank the members of our Trial Steering Committee of the mindfulness-based interventions—teaching assessment
(Chris Leach, Richard Moore, and Glenys Parry) and Data Monitoring criteria (MBI:TAC). Assessment 2013; 20: 681–88.
Committee (Paul Ewings, Andy Field, and Joanne MacKenzie) for their 20 Segal ZV, Teasdale JD, Williams JM, Gemar MC. The
valuable advice and support during the project and Shadi Beshai who mindfulness-based cognitive therapy adherence scale: Inter-rater
completed some of the final research assessments. We acknowledge the reliability, adherence to protocol and treatment distinctiveness.
Clin Psychol Psychother 2002; 9: 131–38.
additional support that has been provided by the Mental Health and
Primary Care Research Networks, and the support provided by the 21 First MB, Spitzer RL, Gibbon M, Williams JBW. The structured
clinical interview for DSM-IV Axis I disorder with psychotic screen.
Department of Health and local Primary Care Trusts in meeting the excess
New York: New York Psychiatric Institute, 1995.
treatment and service support costs associated with the trial. Most
22 Williams JBW. A structured clinical interview guide for the Hamilton
importantly, we are grateful to the participants for their time in taking part
Depression Rating Scale. Arch Gen Psychiatry 1998; 45: 742–47.
in this trial. Finally, we also thank the following colleagues who have
23 Beck AT, Steer RA, Brown GK. The Beck Depression Inventory,
contributed to the PREVENT study, through recruitment and retention of
2nd edn. San Antonio, TX: The Psychological Corporation, 1996.
patients or provision of administrative support: Rebecca Amey,
24 Harper A, Power M. Development of the World Health Organization
Miriam Cohen, Alice Garrood, Nora Goerg, Anna Hunt, Sarah Lane,
WHOQOL-BREF quality of life assessment. Psychol Med 1998;
Mary Sharkey, Cara Simmance, Holly Sugg, Lucy Wootton, and other 28: 551–58.
undergraduates and researchers who provided support to the trial.
25 Brooks R. EuroQol: the current state of play. Health Policy 1996;
References 37: 53–72.
1 Derek R. Prevalence and clinical course of depression: a review. 26 Kabat-Zinn J. An outpatient program in behavioral medicine for
Clin Psychol Rev 2011; 31: 1117–25. chronic pain patients based on the practice of mindfulness
2 Kupfer DJ, Frank E, Perel JM, et al. 5-year outcome for maintenance meditation—theoretical considerations and preliminary-results.
therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73. Gen Hospital Psychiatry 1982; 4: 33–47.
3 National Institute for Health and Clinical Excellence. Depression: 27 The King’s Fund. Paying the price: the cost of mental health care in
the treatment and management of depression in adults (update). England to 2026. London: The Kings Fund, 2008.
Clinical Guideline 90. 2009. 28 Kessler RC, Barber C, Beck A, et al. The World Health Organization
4 Geddes JR, Carney SM, Davies C, et al. Relapse prevention with health and work performance questionnaire (HPQ).
antidepressant drug treatment in depressive disorders: a systematic J Occup Environ Med 2003; 45: 156–74.
review. Lancet 2003; 361: 653–61. 29 NICE. Guide to the methods of technology appraisal. National
5 Williams JMG, Kuyken W. Mindfulness-based cognitive therapy: Institute for Health and Clinical Excellence, 2008.
a promising new approach to preventing depressive relapse. 30 Koopmanschap MA, Rutten FFH. A practical guide for calculating
Br J Psychiatry 2012; 200: 2. indirect costs of disease. Pharmacoeconomics 1996; 10: 460–66.
6 Piet J, Hougaard E. The effect of mindfulness-based cognitive 31 Schafer JL. Multiple imputation: a primer. Stat Methods Med Res
therapy for prevention of relapse in recurrent major depressive 1999; 8: 3–15.
disorder: a systematic review and meta-analysis. Clin Psychol Rev 32 Kuyken W, Bryford S, Byng R, et al. Study protocol for a
2011; 31: 1032–40. randomzed controlled trial comparing mindfulness-based
7 Williams JMG, Crane C, Barnhofer T, et al. Mindfulness-based cognitive therapy with maintenance anti-depressant treatment in
cognitive therapy for preventing relapse in recurrent depression: the prevention of depressive relapse/recurrence: the PREVENT
a randomized dismantling trial. J Consult Clin Psychol 2014; 82: 275–86. trial. Trials 2010; 11: 99.
8 Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for 33 Parker G, Roussos J, Hadzi-Pavlovic D, Mitchell P, Wilhelm K,
depression: replication and exploration of differential relapse Austin MP. The development of a refined measure of dysfunctional
prevention effects. J Consult Clin Psychol 2004; 72: 31–40. parenting and assessment of its relevance in patients with affective
9 Kuyken W, Crane R, Dalgleish T. Does mindfulness based cognitive disorders. Psychol Med 1997; 27: 1193–203.
therapy prevent relapse of depression? BMJ 2012; 345: e7194. 34 Efron B, Tibshirani RJ. An introduction to the bootstrap. New York:
10 Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive Chapman Hall, 1993.
therapy to prevent relapse in recurrent depression. 35 Thompson SG, Barber JA. How should cost data in pragmatic
J Consult Clin Psychol 2008; 76: 966–78. randomised trials be analysed? Br Med J 2000; 320: 1197–200.
11 Kuyken W, Byford S, Byng R, et al. Study protocol for a randomized 36 Stinnett AA, Mullahy J. Net health benefits: a new framework for
controlled trial comparing mindfulness-based cognitive therapy with the analysis of uncertainty in cost-effectiveness analysis.
maintenance anti-depressant treatment in the prevention of Med Decis Making 1998; 18 (2 suppl): S68–80.
depressive relapse/recurrence: the PREVENT trial. Trials 2010; 11: 99. 37 Fenwick E, Byford S. A guide to cost-effectiveness acceptability
12 Kuyken W, Byford S, Byng R, et al. Update to the study protocol for a curves. Br J Psychiatry 2005; 187: 106–08.
randomized controlled trial comparing mindfulness-based cognitive 38 StataCorp. Stata Statistical Software: release 13. College Station, TX:
therapy with maintenance anti-depressant treatment in the StataCorp LP, 2013.
prevention of depressive relapse/recurrence: the PREVENT trial. 39 Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs
Trials 2014; 15: 217. sequential pharmacotherapy and mindfulness-based cognitive
13 British Medical Association, Royal Pharmaceutical Society of therapy, or placebo, for relapse prophylaxis in recurrent depression.
Great Britain. British National Formulary 48. London: BMJ Books/ Arch Gen Psychiatry 2010; 67: 1256–64.
Pharmaceutical Press, 2006. 40 Stangier U, Hilling C, Heidenreich T, et al. Maintenance
14 Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 cognitive-behavioral therapy and manualized psychoeducation in
statement: updated guidelines for reporting parallel group the treatment of recurrent depression: a multicenter prospective
randomized trials. Ann Intern Med 2010; 152: 1–15. randomized controlled trial. Am J Psychiatry 2013; 170: 624–32.
15 Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, Consort 41 Miniati M, Rucci P, Benvenuti A, et al. Clinical characteristics and
Group. Extending the CONSORT statement to randomized trials of treatment outcome of depression in patients with and without a
nonpharmacologic treatment: explanation and elaboration. history of emotional and physical abuse. J Psychiatr Res 2010;
Ann Intern Med 2008; 148: 295–309. 44: 302–09.
16 Williams JBW, Kobak KA, Bech P, et al. The GRID-HAMD: 42 Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of
standardization of the Hamilton depression rating scale. major depressive disorder. Am J Psychiatry 2000; 157: 229–33.
Int Clin Psychopharmacol 2008; 23: 120–29. 43 Bockting CL, Schene AH, Spinhoven P, et al. Preventing relapse/
17 Williams JBW. A structured interview guide for the Hamilton recurrence in recurrent depression with cognitive therapy: a
Depression Rating-Scale. Arch Gen Psychiatry 1988; 45: 742–47. randomized controlled trial. J Consult Clin Psychol 2005; 73: 647–57.